Skip to content
Search

Latest Stories

Roger Scarlett-Smith steps down as head of STADA UK

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK.

The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets.


Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories.

Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

STADA CEO Peter Goldschmidt expressed his sincere appreciation for Scarlett-Smith’s contribution over the past four years. During this time, he led the UK operation through the pandemic, the expansion and refitting of the Thornton & Ross manufacturing facility in Linthwaite, as well as the transfer of the commercial teams into purpose-built offices in nearby Slaithwaite.

Bär Rudolf2659 Rudolf Bär

Bär who will report to STADA’s head of European Markets, Stephan Eder, joined STADA in February 2019 in the role of vice-president Mid-Sized European Markets after more than 20 years’ experience in the pharmaceutical industry, including in Consumer Healthcare, Specialty and Generics.

His prior experience includes a period as head of Central Eastern Europe, Middle East and Africa at PGT, the joint venture between Procter & Gamble and Teva.

He has led STADA’s Mid-Sized European Markets to brink of EUR500 million annual sales by developing agile and entrepreneurial approaches in individual countries. This has included successfully integrating Consumer Healthcare brands acquired from GSK and distributed for Sanofi. Bär, who studied economics and biology, has been married to an English wife for 22 years.

Scarlett-Smith commented: “I am honoured to have served the UK business and the global STADA team. There are phenomenal opportunities ahead for STADA and I wish Rudolf (Bär) all the best as he assumes his wider responsibilities. I would like to thank the UK senior executive committee and everyone in the business both locally and globally for their support.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less